Our principal finding is that while CD4+ and CD8+ TIL populations associate with improved OS in HNSCC, there was considerable heterogeneity in outcomes between different tumor anatomical subsites—previously unreported in the literature. The gene discussed is CD4; the disease is neoplasm.